This post examines why the approval matters, how small-molecule GLP-1 agonists compare with peptides, and what the shift means for patent strategy and the pipeline ahead
[3] Semaglutide is administered as a once-weekly subcutaneous injection, with a recommended titration schedule starting at 0.25mg for four weeks, then 0.5mg, with potential increase to 1mg if needed
GLP-1 users should avoid meals and snacks that are deep-fried, high in sugar or saturated fat, and spicy or acidic, since those foods can worsen side effects and work against weight-loss efforts, Snashall said
Clinicians should inform patients and families of this risk before initiating treatment, particularly in individuals with psychiatric or substance use comorbidities
[DOI] [PubMed] [Google Scholar] Aureli T., Di Cocco M.E., Puccetti C., Ricciolini R., Scalibastri M., Miccheli A., Manetti C., Conti F
PubMed Sompolinsky D, Samra Z